Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: A prospective head-to-head cross-sectional study

British Journal of Dermatology

Volumn 168, Issue 5, 2013, Pages 1012-1018

  Martyn Simmons, C L ^a   Mee, J B ^a   Kirkham, B W ^b   Groves, R W ^a   Milburn, H J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FUMARIC ACID ETHYL ESTER; GAMMA INTERFERON; ISONIAZID PLUS RIFAMPICIN; METHOTREXATE; MYCOBACTERIUM ANTIGEN; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANTIBODY SCREENING; ARTICLE; BIOLOGICAL THERAPY; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; RISK ASSESSMENT; RISK FACTOR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LONDON; MALE; MASS SCREENING; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PSORIASIS; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84876991274     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12176     Document Type: Article

References (29)

1. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
3. Stop TB Partnership and World Health Organization. 2009 Update Tuberculosis Facts. Geneva: World Health Organization, 2009.
4. Vynnycky E, Fine PE,. Lifetime risks, incubation period and serial interval of tuberculosis. Am J Epidemiol 2000; 152: 247-63.
5. Rook GA, Taverne J, Leveton C, et al. The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 1987; 62: 229-34.
6. Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
7. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-5.
8. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
9. Gomez-Reino JJ, Carmona L, Angel Descalzo M,. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61.
10. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
11. Hernandez C, Cetner AS, Jordan JE, et al. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008; 59: 363-80; quiz 82-4.
12. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
13. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-206.
14. Kim EY, Lim JE, Jung JY, et al. Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 2009; 9: 207.
15. Dominguez J, Latorre I, Altet N, et al. IFN-gamma-release assays to diagnose TB infection in the immunocompromised individual. Expert Rev Respir Med 2009; 3: 309-27.
16. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136: 198-204.
17. De Leon P, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 776-81.
18. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ,. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumour necrosis factor treatment. J Rheumatol 2008; 35: 1271-6.
19. Lafitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before anti-tumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800.
20. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune disease. Eur Respir J 2009; 33: 586-93.
21. Lange B, Vavra M, Kern WV, Wagner D,. Indeterminate results of a tuberculosis-specific interferon-gamma release assay in immunocompromised patients. Eur Respir J 2010; 35: 1179-82.
22. Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27: 907-13.
23. Balato N, Ayala F, Gaudiello F, et al. Comparison of tuberculin skin test and interferon-γ assays in patients with moderate to severe psoriasis who are candidates for antitumour necrosis factor-α therapy. Br J Dermatol 2008; 158: 847-8.
24. Altman DG,. Practical Statistics for Medical Research, 1st edn. London: Chapman and Hall, 1991; 403-9.
25. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328-34.
26. Emery P, Panayi GS, Welsh KI, Cole BC,. Relationship of HLA-DR4 to defective cellular immunity in rheumatoid arthritis using PPD, and mycoplasma and lectin mitogens. J Rheumatol 1985; 12: 859-64.
27. Thomas B, Pugalenthi A, Patel H, et al. Concordance between tuberculin skin test and interferon-γ assay and interferon-γ response to mitogen in pediatric tuberculosis contacts. Pediatr Pulmonol 2011; 46: 1225-32.
28. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
29. National Institute for Clinical Excellence. Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. National Institute for Clinical Excellence; Clinical Guideline 117, issued March 2011. Available at: http://www.nice.org.uk/guidance/CG117 (last accessed 29 December 2012).